Dr. Meet Patel

Dr. Meet Patel is a specialist in Nuclear Medicine and Theranostics, with expertise in advanced molecular imaging and targeted radionuclide therapies. He specialises in PET-CT and SPECT-CT imaging, along with targeted treatments such as Lu-177 and I-131 therapies. His clinical and research interests include PSMA imaging and neuro-oncology, with a focus on using molecular imaging to support accurate diagnosis, disease monitoring and personalised treatment planning. He works closely with multidisciplinary teams to integrate molecular imaging and theranostic approaches into patient care.

Dr. Meet Patel has undertaken advanced training in Nuclear Medicine and Theranostics, with clinical exposure to molecular imaging, PET-CT, SPECT-CT and radionuclide therapies.

He also conducted his thesis at Mahatma Gandhi Medical College & Hospital, Jaipur, focusing on the clinical and prognostic value of tracer dynamics in newly diagnosed prostate cancer patients undergoing PSMA PET-CT.

• Performs and interprets PET-CT and SPECT-CT studies for diagnosis and disease monitoring.
• Plans, administers and supervises radionuclide therapies, including I-131 and Lu-177-based treatments.
• Follows radiation safety, quality assurance and institutional protocols.
• Collaborates with multidisciplinary teams for patient management and theranostic planning.

• Nuclear Medicine
• Theranostics
• PET-CT
• SPECT-CT
• PSMA PET-CT
• Molecular Imaging
• Radionuclide Therapy
• Lu-177-based Therapies
• I-131 Therapy
• Neuro-oncology Imaging
• Radiation Safety

Thesis

“To Study the Clinical and Prognostic Value of Tracer Dynamics in Newly Diagnosed Prostate Cancer Patients on Prostate Specific Membrane Antigen (PSMA) PET-CT”
Mahatma Gandhi Medical College & Hospital, Jaipur.

Research Publication

“Is 18F-PSMA PET-CT a reliable imaging modality to evaluate the status of recurrent/residual brain tumors in post-treatment patients?”
Journal of Neuro-Oncology, 2025; 175(2):713–720.
DOI: 10.1007/s11060-025-05167-x.

Case Report

“Extension of Newly Diagnosed Olfactory Neuroblastoma: A Rare Tumour”
Published in October 2024.